Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab.

ABSTRACT:

Importance

In 2023, 2 forms of respiratory syncytial virus (RSV) prevention, maternal RSV vaccine and nirsevimab, became available for infants. The factors that played a role in their uptake during the first 2 seasons remain unclear.

Objective

To describe the rate of RSV immunization through maternal RSV vaccination or nirsevimab during the 2023-2024 and 2024-2025 RSV seasons and identify the factors associated with their receipt.

Design, setting, and participants

This cohort study was performed at clinical sites affiliated with a quaternary care hospital in New York, New York, from October 1, 2023, to March 31, 2024, and October 1, 2024, to March 31, 2025. Participants included infants younger than 8 months who had at least 1 clinical encounter during the 2023-2024 a

SUBMITTER: Acker KP 

PROVIDER: S-EPMC12910395 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature